Regeneron: Drug Pricing Woes Notwithstanding, Due For A Major Comeback

Regeneron Pharmaceuticals (REGN) shares have declined over 50% in the past year, facing pressure from threats to its key drug Eylea by generics and longer-acting therapies, along with some surmountable regulatory setbacks in 2025. Despite this, the company reported 2024 revenues up 8% to $14.2 billion and GAAP net income of $38.34 per share, significantly bolstered by its co-marketed Dupixent, which contributed over $1.4 billion to Regeneron's revenue last quarter. With two new products approved offering over $500 million in peak revenue potential and a promising pipeline, Regeneron aims to drive annual revenues past $20 billion by 2030, signaling a strong long-term growth outlook.

Analysis

Despite a significant >50% decline in its share price over the past 12 months, Regeneron Pharmaceuticals (REGN) exhibits strong underlying fundamentals and a robust growth outlook. The primary headwinds include competitive threats to its key drug, Eylea, from generics and new longer-acting therapies, as well as some manageable regulatory setbacks experienced in 2025. However, these concerns are counterbalanced by strong operational performance, evidenced by an 8% increase in 2024 revenue to $14.2 billion and a GAAP net income of $38.34 per diluted share. A critical growth driver is the co-marketed drug Dupixent, which generated over $1.4 billion for Regeneron in the last quarter alone. Furthermore, the company's pipeline is bolstered by the recent approval of two new products, each with a peak revenue potential exceeding $500 million, supporting management's projection for annual revenues to surpass $20 billion by 2030.

Key Decisions for Investors

• Investors may consider the current valuation a compelling entry point, given the significant disconnect between the >50% share price decline and the company's reported 8% revenue growth and strong forward guidance.
• Monitor the competitive landscape for Eylea closely, as the erosion of its market share by generics or new therapies represents the most significant near-term risk to revenue forecasts.
• Future investment decisions should be heavily weighted on the continued revenue growth of Dupixent and the successful commercial launch of the two newly approved products, which are critical to achieving the projected >$20 billion revenue target by 2030.